active portfolio companies
Investors and Venture Partners spanning Australia, New Zealand, United States and the United Kingdom
Cutting-edge biotech company founded to target neurodegenerative diseases by improving disrupted physiological processes leading to dementia.
Vaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine
Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity